It may be safe to discontinue or deescalate antibiotics in some cancer patients who develop febrile neutropenia (FN) before the condition resolves, but guidelines and studies are not yet fully conclusive, a panel of speakers said during the Hematology/Oncology Pharmacy Association’s 2021 virtual annual conference. Presenters offered evidence for and against early discontinuation of antibiotics.
Marked by fever and absolute neutrophil count (ANC) of less than 500 cells/mm3, FN